European Alliance for Access to Safe Medicines

Tweet this page
Registration as it was on 21 Feb 2023
How to read and use this data card.
Download this datacard


Since 20 September 2021 self-declared 'non-commercial organisations' are no longer required to provide a lobby budget. See above timeline for this registrant's historical lobby budget.

Lobbying Costs

None declared

Financial year: Jan 2022 - Dec 2022

Lobbyists (Full time equivalent)

1 Fte (1)

Lobbyists with EP accreditation


High-level Commission meetings


Lobbying Costs over the years

  • Info

    European Alliance for Access to Safe Medicines   (EAASM)

    EU Transparency Register

    861368611058-84 First registered on 29 Apr 2013

    Goals / Remit

    The EAASM will strive to ensure that most patients within the EU are aware of falsified and substandard medicines and unsafe medical practices and that national governments have put in place mechanisms to protect the population.

    The EAASM through innovative projects and activities will produce tangible and measurable outputs that have a significant bearing on making medicines and medical practices safer for the European population.

    Main EU files targeted

    The EAASM is following closely the implementation of the Falsified Medicines Directive. The EAASM is also involved in activities relating to patient safety in the areas of off label use of medicines, compounding of medicines, regulatory aspects concerning nanomedicines. It has also involved in a major medication error and traceability patient safety project with the aim to significantly reduce medication errors by enhancing traceability processes within the hospital environment.


    Head Office
    12 Camden Road Dublin 8
    Dublin D08 R9CN
    EU Office
    20 MADEIRA PARK Madeira Park


  • People

    Total lobbyists declared


    Employment timeLobbyists

    Lobbyists (Full time equivalent)


    Lobbyists with EP accreditation

    All Lobbyists with EP accreditation over time

    0 accreditations were / are live (in bold) for the selected state of 26 Sep 2023

    Name Start date End Date
    Mr Michael Isles 15 Jun 2022 15 Jun 2023
    Mr Michael Isles 08 Mar 2019 07 Mar 2020
    Mr Michael Isles 20 Nov 2017 15 Nov 2018
    Mr Michael Isles 11 Feb 2016 10 Feb 2017
    Mr Michael Isles 01 Oct 2014 29 Sep 2015

    Complementary Information

    The Executive Director spends up to 3.5 days per week working on EAASM activities. He is paid for this work.

    Person in charge of EU relations

    Data not provided by Register Secretariat due to GDPR

    Person with legal responsibility

    Data not provided by Register Secretariat due to GDPR

  • Categories


    Non-governmental organisations, platforms and networks and similar

  • Networking


    The EAASM is an active member of the Alliance for Safe Online Pharmacy in the EU (ASOP EU) Community Interest Company ( As such, it contributes to the development of this not for profit collaborative group. (Participants in ASOP EU are united by a single mission that together they can create an environment that enables patients to buy their medicines online safely, in countries where it is legal for them to do so). The EAASM is also a civil Society member of the EUIPO/Observatory and is an expert with the Expert group of "Search engines". The EAASM is also a .Pharmacy Executive Board Member. It is an active member of the EU health Coalition as well as having multiple connections to patient safety organisations due it being the secretariat of the ECAMET Alliance and the Nanomedicines Regulatory Coalition.

    Member organisations

    None declared

  • Financial Data

    Interests represented

    Does not represent commercial interests

    Closed financial year

    Jan 2022 - Dec 2022

    Lobbying costs for closed financial year

    Since 20 September 2021 self-declared 'non-commercial organisations' are no longer required to provide a lobby budget. See above timeline for this registrant's historical lobby budget.

    Total organisational budget in closed year


    Major funding types in closed year

    Grants, Member's contribution

    Major contributions in closed year

    Contribution Becton Dickinson 55,178€
    Contribution Bayer 10,000€
    Contribution VIFOR 10,000€

    Other financial info

    None declared

  • EU Structures

    Groups (European Commission)


    Groups (European Parliament)

    Artificial intelligence and digital#Cancer
    Participated in ESNO and PACT meetings and Health First Europe meetings. Also Civil Society member of The Observatory (EUIPO).

    Other activities

    1. The Google AdWord grant was extended for another year in November 2017. It has however now ceased. Whilst it was running though in 5 major UE Member States, would be buyers of medicines are drawn to the educational pages via this Google AdWord grant. Over 35,000 first page impressions were being achieved with a >3% click through rate - this is giving rise to over 1000 visitors per day. Integrated in to the web site is an opportunity to complete a survey. Over 2300 responses have now been received and one of the key questions asked is about a willingness to change behaviour. Overwhelming positive results were revealed with 91% saying they would find an authentic website or revert to their local pharmacy.

    2. The EAASM has entered into a campaign centred around patient safety and intends to heighten awareness of issues relating to safety aspects of unlicensed and off label medicines, adverse event reporting, patient consent and general increased awareness around this topic.
    3. New patient safety projects to do with building a more robust regulatory framework for nanomedicines and two EU Parliament meetings brought about productive discussion and ways forward. The report on the Q3 meeting can be found here In addition a comprehensive report was produced with a clear call to action
    4. A compounding survey is currently being completed by hospital and community pharmacists with a view to sharing best practice to enhance patient safety in this area.
    5. The EAASM recently hosted a sharing best practice meeting on the issues around implementing the safety features within the hospital arena and the report can be found here A follow up round table took place in September 2020 and a report entitled ‘Patient Safety and the Implementation of the Falsified Medicines Directive in the Hospital Environment: Practical solutions and benefits’.
    5. The Executive Director and Secretariat are also very active in presenting at all types of conferences to promulgate the patient safety activities of the EAASM. He spoke at the EAHP 2017 Congress on falsified medicines and the effect of raise awareness amongst the public and thus tackling the demand side to the equation. He has recently published a paper entitled "What’s in a word? Falsified/counterfeit/fake medicines – the definitions debate" which can be found here In addition a report on the status of Member State progress in terms of awareness raising activity has been published which can be found here A detailed report entitled Patient Safety and Nanomedicines - the need for a centralised regulatory procedure will be published by end April 2020. In addition a briefing document is available now so that all areas can understand the complex patient safety issues connected with robust regulatory procedures and analysis. Similarly the European Medication Error and Traceability patient safety project is now well under way with the establishment of a Scientific Committee and a website nearing completion.

  • Meetings


    None declared

Download this datacard